Skip to content

Kyoto Congestive Heart Failure Study

Kyoto Congestive Heart Failure Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02334891
Acronym
KCHF
Enrollment
4056
Registered
2015-01-08
Start date
2014-10-31
Completion date
2021-03-30
Last updated
2021-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure, Elderly Frail, Guideline Adherence, Heart Failure, Diastolic, Heart Failure, Systolic

Keywords

congestive heart failure, heart failure, diastolic, heart failure, systolic, elderly frail, guideline adherence

Brief summary

The purpose of this study is to investigate the patient characteristics, selection of treatment, and factors associated with clinical outcomes in Japanese patients with acutely decompensated congestive heart failure.

Detailed description

Congestive heart failure (CHF) has been markedly increasing in Japan due to the rapid aging of the society and the Westernization of lifestyle that facilitates the development of coronary artery disease. The prognosis of patients with CHF still remains poor, despite the recent advances in medical and surgical treatment. Elderly heart failure patients with preserved ejection and multiple comorbidity may account for significant portion among CHF patients in the real world clinical practice, however; most of previous prospective cohort studies excluded these patients. The KCHF registry, an all-comer, prospective, multicenter registry, was designed to investigate all patients who admitted to the hospital due to acutly decompensated CHF. The aim of this study was to clarify the patients characteristics , selection of treatment, and prognosis of patients with acutly decompensated CHF in the real-world clinical practice in Japan.

Interventions

OTHERStandard

Standard management

Sponsors

Kyoto University, Graduate School of Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All patients who admitted to the participating centers due to acutly decompensated CHF defined by modified Framingham criteria * Patients who underwent heart failure treatment including intravenus drug

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
hospital mortality1-year

Secondary

MeasureTime frame
improvement of dyspnea level at discharge measured by Likert scale1-year
walking ability at discharge categorized by ambulatory, wheelchair (outdoor only), wheelchair (outdoor and indoor), bedridden1-year
any severe ventricular arrhythmic event during hospitalization1-year
onset of atrial fibrillation events during hospitalization1-year
any bradyarrhythmic event during hospitalization1-year
any stroke during hospitalization1-year
any cardiac surgery during hospitalization1-year
any cateter intervention during hospitalization1-year
functional level at discharge measured by NYHA classification1-year
bleeding events during hospitalization (GUSTO definition; moderate to severe)1-year
adverse drug events during hospitalization1-year
infectious diseases during hospitalization1-year
change of BNP at discharge (≧30% compared to BNP at admission )1-year
worsening renal function at discharge (raise of Cr≧0.3mg/dl compared to Cr at admission )1-year
usage of guideline recommended medicine during hospitalization1-year
usage of tolvaptan during hospitalization1-year
any device implantation during hospitalization1-year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026